Tumor angiogenesis. From bench to bedside

Domenico Ribatti, Beatrice Nico

Research output: Contribution to journalArticle

Abstract

Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research has a solid scientific foundation. More than 30 years ago, Folkman found a revolutionary new way to think about cancer. He postulated that in order to survive and grow, tumors require blood vessels and that by cutting off the blood supply a cancer could be starved into remission. Several clinical studies have shown a positive correlation between the number of vessels in the tumor, metastasis formation and prognosis. The genetic instability of tumor cells permits the occurrence of multiple genetic alterations that facilitate tumor progression and metastasis, and cell clones with diverse biological aggressiveness may coexist within the same tumor. These two properties allow tumors to acquire resistance to cytotoxic agents. Inhibiting angiogenesis is a major area of therapeutic development for the treatment of cancer. Whereas conventional chemotherapy, radiotherapy and immunotherapy are directed against tumor cells, anti-angiogenic therapy is aimed at the vasculature of a tumor and will either cause total tumor regression or keep tumors in a state of dormancy. Even though numerous compounds inhibit angiogenesis, few of them have proved effective in vivo, and only a couple of agents have been able to induce tumor regression. Bevacizumab is considered to be the first specific angiogenesis inhibitor for clinical oncology.

Original languageEnglish
Pages (from-to)12-19
Number of pages8
JournalItalian Journal of Anatomy and Embryology
Volume121
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Neoplasms
Vascular Tissue Neoplasms
Neoplasm Metastasis
Angiogenesis Inhibitors
Medical Oncology
Cytotoxins
Immunotherapy
Radiotherapy
Therapeutics
Clone Cells
Drug Therapy
Growth
Research

Keywords

  • Angiogenesis
  • Anti-angiogenesis
  • Tumor progression

ASJC Scopus subject areas

  • Anatomy
  • Embryology

Cite this

Tumor angiogenesis. From bench to bedside. / Ribatti, Domenico; Nico, Beatrice.

In: Italian Journal of Anatomy and Embryology, Vol. 121, No. 1, 2016, p. 12-19.

Research output: Contribution to journalArticle

Ribatti, Domenico ; Nico, Beatrice. / Tumor angiogenesis. From bench to bedside. In: Italian Journal of Anatomy and Embryology. 2016 ; Vol. 121, No. 1. pp. 12-19.
@article{ca45de2adada4b8eb74297a604649915,
title = "Tumor angiogenesis. From bench to bedside",
abstract = "Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research has a solid scientific foundation. More than 30 years ago, Folkman found a revolutionary new way to think about cancer. He postulated that in order to survive and grow, tumors require blood vessels and that by cutting off the blood supply a cancer could be starved into remission. Several clinical studies have shown a positive correlation between the number of vessels in the tumor, metastasis formation and prognosis. The genetic instability of tumor cells permits the occurrence of multiple genetic alterations that facilitate tumor progression and metastasis, and cell clones with diverse biological aggressiveness may coexist within the same tumor. These two properties allow tumors to acquire resistance to cytotoxic agents. Inhibiting angiogenesis is a major area of therapeutic development for the treatment of cancer. Whereas conventional chemotherapy, radiotherapy and immunotherapy are directed against tumor cells, anti-angiogenic therapy is aimed at the vasculature of a tumor and will either cause total tumor regression or keep tumors in a state of dormancy. Even though numerous compounds inhibit angiogenesis, few of them have proved effective in vivo, and only a couple of agents have been able to induce tumor regression. Bevacizumab is considered to be the first specific angiogenesis inhibitor for clinical oncology.",
keywords = "Angiogenesis, Anti-angiogenesis, Tumor progression",
author = "Domenico Ribatti and Beatrice Nico",
year = "2016",
doi = "10.13128/IJAE-18340",
language = "English",
volume = "121",
pages = "12--19",
journal = "Italian Journal of Anatomy and Embryology",
issn = "1122-6714",
publisher = "Firenze University Press",
number = "1",

}

TY - JOUR

T1 - Tumor angiogenesis. From bench to bedside

AU - Ribatti, Domenico

AU - Nico, Beatrice

PY - 2016

Y1 - 2016

N2 - Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research has a solid scientific foundation. More than 30 years ago, Folkman found a revolutionary new way to think about cancer. He postulated that in order to survive and grow, tumors require blood vessels and that by cutting off the blood supply a cancer could be starved into remission. Several clinical studies have shown a positive correlation between the number of vessels in the tumor, metastasis formation and prognosis. The genetic instability of tumor cells permits the occurrence of multiple genetic alterations that facilitate tumor progression and metastasis, and cell clones with diverse biological aggressiveness may coexist within the same tumor. These two properties allow tumors to acquire resistance to cytotoxic agents. Inhibiting angiogenesis is a major area of therapeutic development for the treatment of cancer. Whereas conventional chemotherapy, radiotherapy and immunotherapy are directed against tumor cells, anti-angiogenic therapy is aimed at the vasculature of a tumor and will either cause total tumor regression or keep tumors in a state of dormancy. Even though numerous compounds inhibit angiogenesis, few of them have proved effective in vivo, and only a couple of agents have been able to induce tumor regression. Bevacizumab is considered to be the first specific angiogenesis inhibitor for clinical oncology.

AB - Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research has a solid scientific foundation. More than 30 years ago, Folkman found a revolutionary new way to think about cancer. He postulated that in order to survive and grow, tumors require blood vessels and that by cutting off the blood supply a cancer could be starved into remission. Several clinical studies have shown a positive correlation between the number of vessels in the tumor, metastasis formation and prognosis. The genetic instability of tumor cells permits the occurrence of multiple genetic alterations that facilitate tumor progression and metastasis, and cell clones with diverse biological aggressiveness may coexist within the same tumor. These two properties allow tumors to acquire resistance to cytotoxic agents. Inhibiting angiogenesis is a major area of therapeutic development for the treatment of cancer. Whereas conventional chemotherapy, radiotherapy and immunotherapy are directed against tumor cells, anti-angiogenic therapy is aimed at the vasculature of a tumor and will either cause total tumor regression or keep tumors in a state of dormancy. Even though numerous compounds inhibit angiogenesis, few of them have proved effective in vivo, and only a couple of agents have been able to induce tumor regression. Bevacizumab is considered to be the first specific angiogenesis inhibitor for clinical oncology.

KW - Angiogenesis

KW - Anti-angiogenesis

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=84973454833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973454833&partnerID=8YFLogxK

U2 - 10.13128/IJAE-18340

DO - 10.13128/IJAE-18340

M3 - Article

AN - SCOPUS:84973454833

VL - 121

SP - 12

EP - 19

JO - Italian Journal of Anatomy and Embryology

JF - Italian Journal of Anatomy and Embryology

SN - 1122-6714

IS - 1

ER -